patients with arthritis (63.2%) and chronic arthritis (69.6%) than the whole cohort (53.8%). Erythrocyte sedimentation rate and CRP level were in high levels even during attackfree period in 13.9% (n = 97/697) and 11% (n = 78/670) of the patients, respectively. Proteinuria was found in ten patients (1.4%). Amyloidosis was confirmed by renal biopsy in only two of these cases who were homozygous for M694V and compound heterozygous for M694V/M680I. 47 (6.6%) subjects were considered as colchicine resistant. Homozygote M694V mutation was the most frequent mutation in those resistant cases (63.8%, n = 30), followed by compound heterozygote mutation of M694V/M680I (6.3%, n = 3). Homozygous M694V mutation are still the most frequent mutation and associated with the most severe clinical picture and the worst outcome in Turkish children. M694V genotype seems to be more frequently associated with arthritis as well as with chronic arthritis than other genotypes. Recurrence of FMF episodes as well as amyloidosis could only be managed via strict compliance to colchicine treatment. Frequency of amyloidosis significantly decreased compared to the previous studies. A favorable outcome could be obtained with the anti IL-1 in colchicine-resistant FMF patients.
Introduction
Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease that generally present with recurrent episodes of self-limiting polyserositis and arthritis [1, 2] . It is mostly seen among particular ethnic groups such as Turkish, Armenian, Arabic, and Jewish ancestry. Autosomal recessive mutations in MEFV gene is generally responsible for the clinical manifestations of familial Mediterranean fever [3, 4] . FMF usually manifests at early ages and nearly 90% of the patients experience their first attack before 20 years of age [5] .
Colchicine is the main treatment option which is very effective in decreasing the attack frequency as well as in prevention of amyloidosis [6] . Despite good compliance and adequate doses of colchicine, children suffering from at least one attack in a month for three consecutive months are considered as resistant to colchicine [7] . In these particular cases, anti-interleukin 1 agents are suggested to be effective in decreasing attack frequency and severity [8, 9] .
There is lack of updated data in pediatric FMF; namely the relationship of MEFV gene mutations with clinical features, treatment options and efficacy and outcome. Moreover, less is known about outcome/amyloidosis after introduction of anti-IL1 agents into treatment era and efficacy of these biologic agents.
Alterations in routine clinical practise such as diagnostic and resistance criteria in use, treatment options between different clinics in multi-center FMF studies hampers the optimal analysis of results. Hence, this study is of great importance in to evaluate the largest single-center pediatric FMF cohort.
Materials and methods
We have enrolled 708 patients diagnosed with FMF according to the Turkish pediatric FMF criteria. Presence of two or more following criteria in a patient was accepted as diagnostic criteria for FMF; ≥3 attacks with 6-72 h duration of fever, abdominal pain, chest pain, oligoarthritis, and positive family history [5] . Arthritis lasted more than 6 weeks in a subject diagnosed with FMF according to these criteria was attributed as chronic arthritis. Subsequently, antinuclear antibody (ANA) and HLA B27 tests were studied and finally subclassification was made according to juvenile idiopathic arthritis (JIA) diagnostic criteria of International League of Associations for Rheumatology (ILAR) [10] . Laboratory findings and MEFV gene mutation analysis and clinical data were also obtained from the patient files in a retrospective manner.
Only the patients who were on colchicine treatment at least 6 months were included in the study. The alternative treatment options for the resistant cases were also stated and the response to these treatments was also evaluated. Among the adverse effects related to colchicine therapy, the presence of diarrhea and/or alopecia were asked to the patients or parents. Laboratory findings such as hypertransaminasemia and leucopenia are obtained from the files.
The resistance to colchicine treatment was defined as experiencing at least one attack per month in last 3 months despite sufficient doses of colchicine and appropriate drug compliance [7] . According to this recommendation [11] , the standard dose of colchicine is 1.2 mg/m 2 /day. For children younger than 5 years, the dose was 0.5, 1 mg/day for children between 5-10 and 1.5 mg/day for children older than 10. The maximum tolerable dose was used in colchicine-resistant FMF patients with carefully monitoring drug adverse effects (maximum 1.5 mg/day for patients between 5 and 10 years and maximum 2 mg/day for patients older than 10). Our first-step treatment strategy for resistant cases is to increase colchicine to the highest tolerable dose. If complaints persist, the second step is to change the medication with a different brand of colchicine. In our clinical practise, some patients anyhow show favorable clinical response to this switch. If the subjects are still resistant to these treatment options, finally biological agents are introduced into the therapy along with colchicine.
Cerrahpasa Medical School ethics committee approved this study (166591).
Genetic analysis of MEFV gene
Only known mutations (E148Q, R202Q in exon 2, P369S in exon 3, F479L mutation in exon 5, and M694V, M694I, M680I (G/C), M680I (G/A), K695R, R761H, V726A, A744S in exon 10) that have been associated with FMF are investigated in our routine clinical practise. The DNA isolation from blood samples was done according to standard procedures. The assay is based on polymerase chain reaction (PCR) and reverse hybridization method (FMF StripAssay, ViennaLab).
Statistical evaluation
We performed descriptive statistics in this study. The ratios and mean values are calculated with SPSS 14.0 programme (SPSS Inc., Chicago, IL, USA). The mean ± SD values were used for variables with normal distribution, while the median (IQR) values were used for variables that were not normally distributed. The categorical variables are expressed by frequency.
Results

Demographic and clinical features
The demographic and clinical data are summarized in Table 1 . The FMF attacks prior to the study time were evaluated comprehensively in terms of clinical features (Table 1) . Abdominal pain and fever were the most frequently reported manifestations by the patients. Among the 708 patients diagnosed with FMF; arthritis was defined in 288 (40.7%) cases ( Table 2 ). Interestingly, 39 subjects (5.5%) diagnosed with FMF solely after recurrent arthritis attacks without any fever and serositis. Among the large joints, the shoulder girdle was the least frequently affected joint that has involved in only one patient. The mean age of the subjects with arthritis was 5.2 ± 3.7 years at disease onset and the 8.1 ± 4.0 years at diagnosis. The distribution of MEFV gene mutations of the patients with arthritis are given in Table 2 . The median duration of the FMF episodes in children that primarily manifested with articular symptoms was longer than in patients manifested with fever and abdominal pain episodes [72 (IQR 48-168) versus 48 (IQR 24-72) h]. Virtually all articular findings were self-limited processes with no sequel and mainly in the form of acute monoarthritis. However, arthritis in 23 (8%) of the 288 cases was not self-limited; that 13 patients were diagnosed as oligoarticular juvenile idiopathic arthritis (JIA), 9 patients as enthesitis-related arthritis (ERA) and 1 patient as seropositive polyarticular JIA. ANA test was positive in seven (53.8%) patients with oligoarticular JIA. Five (55.5%) of the nine ERA cases were found to be HLA B27 positive. MEFV gene mutations of the children with FMF and chronic arthritis were as follows: four (17.4%) patients were homozygous for M694V, four (17.4%) patients were compound heterozygous for M694V/M680I, two (8.7%) patients were homozygous for V726A, three patients were homozygous for R202Q, and eight (34.7%) patients were carrying heterozygous M694V mutation in only one allele. Although no mutation was detected in two patients, they have been experiencing clinical FMF attacks and have showed favorable response to colchicine. FMF was associated with vasculitis in some patients: in eight patients (1.1%) with Henoch-Schonlein purpura, in two (0.3%) with polyarteritis nodosa and in three (0.4%) with Behcet disease. Apparent pericardial effusion was detected in two patients (0.3%) with echocardiography (MEFV gene analysis; not available in one patient and the other has V726A heterozygous mutation). Prior to the diagnosis of FMF, although 38 patients (5.4%) had underwent appendectomy, the FMF attacks did not subside and diagnosed finally with FMF.
Laboratory findings and amyloidosis
Laboratory investigations are presented in Table 1 . Even during attack-free period, ESR and CRP have remained elevated (ESR >20 mm/h and CRP > 0.5 mg/dL) in 13.9% (n = 97/697) and 11% (n = 78/670) of the patients, respectively. In these subjects, the median level of ESR and CRP were 30 mm/h (range 21-66 mm/h, IQR 25-38) and 1.5 mg/ dL (range 0.6-9.7 mg/dL, IQR 0.9-3.3), respectively. Thrombocytosis, with platelet count above 450000/mm 3 , was detected in 27 (3.8%) of the cases during attacks. The FMF patients without any other chronic disease had normal thrombocyte count in the attack-free period. Anemia, with hemoglobin level below 11 g/dL, was found in 44 (6.2%) patients. Homozygote M694V mutation was detected in 29.6% of the patients with thrombocytosis and 47.7% with anemia. The frequency of M694V homozygosity was higher in these two groups compared to the whole FMF cohort (21.8%). Proteinuria was seen only in ten (1.4%) cases from the onset of disease that 50% (n = 5) of them were homozygous for M694V. Among them, amyloidosis was detected only in two cases (0.3%) and both of them were noncompliant to colchicine treatment. While one of them was a 20-year-old M694V homozygous patient, the other subject was an 18-year-old subject that was compound heterozygous for M694V/M680I.
MEFV gene mutation analysis
The MEFV gene analysis was not performed in 91 subjects. Gene analysis was performed in 617 patients and the genotypes of the MEFV gene are shown in Table 3 . The most common MEFV mutation patterns were homozygous (21.8%) and heterozygous (19.2%) mutations of M694V, followed by M694V/M680I mutation (7.2%). Compound heterozygous mutation of M694V with another exon 10 mutation was found in 11% of the subjects. None of the known mutations could be identified in 6.9% of the patients.
Treatment response and adverse effects
The mean colchicine dosage was 1.23 ± 0.3 mg in all of the subjects. 57 (8.1%) of the patients were regarded as noncompliant to treatment. Among the adverse effects of colchicine therapy, diarrhea was the most frequently seen entity. Average dose of colchicine was higher in these patients (1.4 ± 0.4 mg) compared to the cases that have not experienced diarrhea (1.2 ± 0.3 mg). Liver transaminase elevation was detected only in ten (1.4%) patients and only one patient presented with leukopenia which is thought to be related with colchicine therapy. Alopecia was seen only in one patient. Over the previous 1 year period, 559 (79%) patients with good colchicine compliance have never experienced any attack. However, 149 (21%) patients were still experiencing attacks [median 3 (IQR 2-6)] despite the colchicine treatment. Duration of the episodes were median 24 (IQR 24-48) h. According to the resistance criteria that has been stated in methods, 6.6% (n = 47) of our patients were considered as colchicine-resistant FMF. M694V/M694V (n = 30, 63.8%) and M694V/M680I (n = 3, 6.4%) were the most frequently detected MEFV genotypes in these resistant children (Table 4 ). Of the colchicine-resistant FMF patients, 4 (8.5%) were treated with anakinra (dose 5 mg/ kg/day, maximum dose 100 mg/day) and 12 (25.5%) were treated with canakinumab (dose 4 mg/kg/2 months, maximum dose 150 mg/2 months). All of these patients showed a good clinical response to anti-IL1 agents. The remaining 31 (66%) subjects showed partial or complete response to a different brand of colchicine. four (17.4%) patients with both FMF and JIA were treated with etanercept and three (13%) with adalimumab. Those patients were not included in the colchicine-resistant FMF patients' group.
Discussion
In this study; the clinical findings, mutation analysis, articular involvement, progress to chronic arthritis, and treatment responses are elaborated in a large cohort of pediatric FMF patients. FMF incidence was reported to be equal between genders [12, 13] . In our cohort, female to male ratio was 0.96, which is consistent with the findings of the current literature.
The mean age of the subjects with articular involvement both at disease onset (5.2 ± 3.7 versus 4.8 ± 3.4 years) and at diagnosis (8.1 ± 4 versus 7.3 ± 3.8 years) was slightly higher compared to the whole cohort. In studies from Turkey, the mean age at disease onset was 5.3-5.4 years and mean age at diagnosis was 7.6-8.4 years [14, 15] , which is quite similar to our results. FMF is childhood onset autoinflammatory disease that first episodes usually start before 10-years of age. In a study from Syria, recurrent episodes of FMF are first seen in 85.5% of the subjects before 10 and 58.3% before 5-years of age [13] . Of our subjects, 654 (92.4%) patients showed initial symptoms of the disease before the age of 10, 462 (65.3%) before the age of 5 and 107 (15.1%) before the age of 2. Together with the data from the literature, we can conclude that FMF seems to be an early onset disease that the majority of patients presented before the age of 10.
It is well known that family history plays an important role in the diagnosis of this autosomal recessive disease. In our study, 370 cases (52.3%) had a positive family history. A similar percentage of 58.5% was found in a previous study from Turkey [14] . In the general population of Turkey, consanguinity rate is between 20 and 25% [16] . In our study, consanguinity ratio was slightly higher compared to the general population as expected from autosomal recessive diseases. Presence of consanguinity and family history may be used as a supportive factor in the diagnosis of FMF.
Abdominal pain is one of the most relevant symptoms experienced during FMF attack. It is characterized by severe tenderness like an acute abdomen lasting for at least 6 h [5] . Previous studies reported abdominal pain in 82-96% of patients [7, 17] , which is similar to our results (89.5%).
Chest pain is also seen during the FMF attack, as a result of serositis and pleurisy. Its frequency is reported as 31-84% in previous studies [17] . In a study from Turkey among pediatric patients, chest pain was found in 18% of patients [14] . In our study, the frequency of chest pain was found in 17.2% of patients. The large discrepancy in the frequency of chest pain may be attributed to the differences between age groups included in the studies.
The most common articular involvement of FMF are large joints of the lower extremities with non-migrating acute monoarthritis without any sequelae [5] . In our cohort, the most frequently affected joints were ankle and knees, followed by hip joint (without ankyloses). Particularly, recurrent arthritis of the hip joint may be related to FMF and adequate treatment with colchicine can prevent recurrent episodes of arthritis [18] . In studies among different ethnic groups, the frequency of the articular involvement varies significantly; from 26 to 37% in the Arabic population [13, 19] to 47% in Turkey [20] . The frequency of arthritis was quite high among Sephardic Jews, around 78% [21] . In our cohort, arthritis was seen in 40.7% of the patients. The differences in arthritis frequency among various societies may be related to the differences in distribution of MEFV gene mutations. The M694V mutation is possibly responsible for the most severe clinical presentation of FMF, as well as for the high frequency of arthritis [20] . M694V homozygote mutation was detected in 36.1% (n = 104) of the subjects with arthritis, whereas only 21.8% of whole cohort were homozygous for M694V. Chronic arthritis was recorded in less than 10% of patients diagnosed with FMF [22] . Among our patients with articular involvement (40.7%); eventually 9 of them were diagnosed with ERA, 13 with oligoarticular JIA and 1 with seropositive polyarticular JIA. Of the 23 subjects with chronic arthritis, M694V mutation was present in either homozygous or heterozygous form in 16 patients (69.6%). This rate was higher than the whole cohort (53.8%) and the group with arthritis (63.2%). Moreover, the risk of chronicity in articular involvement seems higher in M694V-positive subjects with arthritis than the M694V-negative subjects with arthritis.
Exertional leg pain was reported to be associated with a more severe phenotype [23] . The frequency of this symptom was found in 58.2% of the FMF subjects. In our study, 66% of our cohort reported exertional leg pain. The value of exertional leg pain as a diagnostic criterion should be clarified by future prospective studies.
Erysipelas-like erythema (ELE) is mostly seen on the anterior side of the ankle and the dorsum of the foot and is probably the most characteristic sign of FMF. The frequency of ELE varies widely between 3 and 46% in the literature [24, 25] . ELE frequency was higher among patients with M694V homozygote mutation (55%), whereas it was about 30.1% among all cohort in our study.
In general, acute phase reactants, namely CRP and ESR usually increase during FMF attack and decrease to normal levels between episodes [26] . Continuous increase even between attacks is suggestive of subclinical inflammation. In a previous study, subclinical inflammation was found in 20% of the subjects, of whom 50% were homozygous for M694V mutation [27] . Subclinical inflammation has also shown to be associated with amyloidosis [27, 28] . Even during attack-free period, ESR and CRP have not decreased to normal levels in 13.9 and 11.6% of our patients, respectively. Among the patients with ongoing subclinical inflammation, 56.4% (n = 44/78) had homozygote M694V mutation. Anemia is frequently reported in patients with recurrent FMF attacks [29] . It was remarkable in 6.2% (n = 44/708) of our subjects. Majority of the patients in this group were M694V homozygote (47.7%, n = 21/44) and resistant to colchicine.
About 20% of general population in Turkey is carrier of a MEFV mutation. The most prevalent mutations are M694V, E148Q, M680I, V726A, and M694I, which constitute the 74% of all FMF mutations [30] [31] [32] . Similarly, these mutations are detected in 77% of our cohort. The most commonly reported MEFV mutations across different studies are summarized in Table 5 . The frequency of M694V mutation in our cohort was similar with the Jewish patients, but it was higher than Arabic and Armenian populations [17] . Following M694V, M680I mutation was second in frequency as in Armenian population. However, V726A was the second most frequent mutation in Arabic population.
Colchicine is the first and the most cost-effective treatment option to prevent secondary amyloidosis in FMF patients. Complete response, partial response, and resistance to colchicine have varied considerably across different studies. While 51.2-68% of the subjects showed complete response, 27.5-46% had partial response [20, 33] . Resistance to colchicine treatment has ranged from 2.7 to 10% [7, 14, 20, 33] . Of our subjects, 47 patients (6.6%) were considered as resistant to colchicine. The frequency of M694V homozygosity was higher in non-responders compared to the good responders 63.8% in colchicine-resistant subjects, 28.4% in partial responders and 17% in complete responders (Table 4 ). Lower percentage of resistance could be explained by the lower frequency of M694V mutation in studied childhood cohort [14] . There are some limitations in our study. First, this is an observational retrospective cohort study, not prospective in nature. Data were collected from patients and their parents at the time of visit and some information is taken from patient files. Molecular MEFV gene investigations were not performed in some of the patients, particularly in those that had diagnosed long ago before the time when our laboratory had started MEFV gene analysis.
In conclusion, FMF diagnosis should be made according to clinical criteria but MEFV gene analysis may give clues about which patients are more likely to experience severe attacks and have a poor clinical outcome. M694V mutation which is the most frequent genotype of FMF, causes the most severe clinical features. M694V genotype is more frequently associated with arthritis as well as chronic arthritis than other genotypes. Exertional leg pain was detected more frequently than expected. Thus, it may be a valuable finding in the diagnosis of FMF. However, future prospective studies are needed to clarify whether it could be a diagnostic criterion or not.
FMF patients with prolonged joint complaints should be screened for possible JIA coexistence and additional immunosuppressive agents should be administered to prevent sequelae of chronic arthritis. Before regarding an FMF patient as colchicine resistant, first, compliance then adequacy of treatment should be ensured. Anti-IL1 agents seem quite effective in management of colchicine-resistant FMF attacks plus prevention of amyloidosis. The significant decrease in frequency of amyloidosis compared to the past, could be related to better follow-up of patients. A favorable outcome could be obtained with the anti IL-1 agents in colchicine-resistant FMF patients.
Compliance with ethical standards
Conflicts of interest All the authors declare no conflict of interest.
Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Cerrahpasa Medical School ethics committee approved this study (166591).
Informed consent
Informed consent was obtained from all individual participants included in the study.
Funding No specific funding was received from any organization for this paper.
